Preliminary Study of Serum Biomarkers Associated With Delirium After Major Cardiac Surgery.
FGF
cardiac surgery
cardiopulmonary bypass
cognition
delirium
fibroblast growth factor
inflammation
metabolism
neurodegeneration
Journal
Journal of cardiothoracic and vascular anesthesia
ISSN: 1532-8422
Titre abrégé: J Cardiothorac Vasc Anesth
Pays: United States
ID NLM: 9110208
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
received:
08
02
2021
revised:
30
04
2021
accepted:
03
05
2021
pubmed:
12
6
2021
medline:
1
2
2022
entrez:
11
6
2021
Statut:
ppublish
Résumé
The objective of this study was to identify novel serum biomarkers specific to postoperative delirium after major cardiac surgery to provide insight into the pathologic processes involved in delirium and its sequelae. Nested, case-control study. Cardiac surgical intensive care unit in a single-site hospital setting. The study comprised 24 older adults (aged >60 years) undergoing major cardiac surgery with cardiopulmonary bypass. None. The primary outcome was a positive screen for delirium from postoperative days one through three based on criteria included in the long form of the Confusion Assessment Method. A multiplexed proteomic approach was applied using proximity extension assays to identify and quantify proteins found in serum collected on the day of surgery and postoperative day one in delirious and nondelirious patient cohorts. An increase in serum fibroblast growth factor (FGF)-21 levels was identified in the delirious cohort from a presurgery baseline of (mean ± standard deviation) 5.0 ± 1.1 log2 abundance (95% confidence interval [CI], 4.3-5.7) to 6.7 ± 1.6 log2 abundance (95% CI, 5.7-7.7; p = 0.01) postsurgery. A similar increase was identified in FGF-23 from a presurgery baseline of 1.7 ± 1.3 log2 abundance (95% CI, 0.8-2.5) to 3.4 ± 2.2 log2 abundance (95% CI, 2.0-4.8; p = 0.06) postsurgery. An increase in interleukin-6 serum levels also was identified in the delirious cohort from a presurgery baseline of 3.8 ± 1.1 log2 abundance (95% CI, 3.1-4.5) to 8.7 ± 1.9 log2 abundance (95% CI, 7.5-9.9; p < 0.0001) postsurgery. However, the increase in interleukin-6 serum levels of the nondelirious cohort also met the study's threshold for statistical significance (p < 0.0001). Finally, an increase in monocyte chemotactic protein-3 serum levels was identified in the delirious cohort from a presurgery baseline of 4.1 ± 0.9 log2 abundance (95% CI, 3.6-4.7) to 6.1 ± 2.0 log2 abundance (95% CI, 4.8-7; p = 0.009) postsurgery. FGF-21, FGF-23, interleukin-6, and monocyte chemotactic protein-3 serum levels were increased postoperatively in patients who developed delirium after major cardiac surgery. This study identified two members of the FGF family as potential putative systemic biomarkers for postoperative delirium after cardiac surgery, suggesting a possible role for metabolic recovery in the pathophysiologic mechanisms underlying neurocognitive dysfunction.
Identifiants
pubmed: 34112563
pii: S1053-0770(21)00372-4
doi: 10.1053/j.jvca.2021.05.002
pmc: PMC8586054
mid: NIHMS1703598
pii:
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
118-124Subventions
Organisme : NHLBI NIH HHS
ID : K08 HL140200
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG053582
Pays : United States
Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare no conflict of interest.
Références
JAMA. 1990 Feb 23;263(8):1097-101
pubmed: 2299782
Cell. 2013 Jun 6;153(6):1194-217
pubmed: 23746838
Lancet. 2002 Jul 20;360(9328):219-23
pubmed: 12133657
Nat Med. 2019 Feb;25(2):270-276
pubmed: 30643288
Diabetes Care. 2011 Sep;34(9):2113-5
pubmed: 21750278
Nucleic Acids Res. 2011 Aug;39(15):e102
pubmed: 21646338
Cell Rep. 2019 Jun 4;27(10):2934-2947.e3
pubmed: 31167139
J Gerontol A Biol Sci Med Sci. 2019 Jan 16;74(2):261-268
pubmed: 29529166
Horm Behav. 2016 Sep;85:86-95
pubmed: 27566237
PLoS One. 2019 Mar 4;14(3):e0213321
pubmed: 30830941
Nat Med. 2013 Sep;19(9):1147-52
pubmed: 23933984
Ann Neurol. 1994 Nov;36(5):747-51
pubmed: 7979220
J Clin Epidemiol. 2008 Jan;61(1):17-33
pubmed: 18083459
West J Emerg Med. 2011 Feb;12(1):77-83
pubmed: 21691475
PLoS One. 2014 Apr 22;9(4):e95192
pubmed: 24755770
Qual Life Res. 2009 Sep;18(7):873-80
pubmed: 19543809
PLoS One. 2019 Dec 19;14(12):e0226412
pubmed: 31856187
PLoS One. 2020 Dec 11;15(12):e0243872
pubmed: 33306729
Pain. 2010 Jul;150(1):173-182
pubmed: 20554116
J Neurosci. 2001 May 1;21(9):3017-23
pubmed: 11312286
Nat Rev Endocrinol. 2020 Nov;16(11):654-667
pubmed: 32764725
Cell Metab. 2013 Sep 3;18(3):333-40
pubmed: 24011069
J Am Geriatr Soc. 1997 Feb;45(2):174-8
pubmed: 9033515
J Am Geriatr Soc. 2017 Aug;65(8):e109-e116
pubmed: 28555781
Endocr Res. 2011;36(4):142-8
pubmed: 21973233
J Clin Epidemiol. 2010 Nov;63(11):1179-94
pubmed: 20685078
Cell Metab. 2016 Mar 8;23(3):441-53
pubmed: 26853749
J Cell Physiol. 2008 Apr;215(1):1-7
pubmed: 18064602
J Biol Chem. 2006 Mar 10;281(10):6120-3
pubmed: 16436388
N Engl J Med. 2006 Mar 16;354(11):1157-65
pubmed: 16540616
Biomed Pharmacother. 2018 Jan;97:1663-1672
pubmed: 29793329
Nat Commun. 2019 Dec 20;10(1):5816
pubmed: 31862977
BMJ Open. 2018 Apr 20;8(4):e020316
pubmed: 29678977
JAMA Surg. 2021 May 1;156(5):430-442
pubmed: 33625501
Int J Geriatr Psychiatry. 2018 Nov;33(11):1428-1457
pubmed: 29278283
J Clin Invest. 2005 Jun;115(6):1627-35
pubmed: 15902306
Lancet Neurol. 2011 Sep;10(9):806-18
pubmed: 21820356
Hemodial Int. 2014 Jan;18(1):78-86
pubmed: 24164913
J Bone Miner Res. 2004 Mar;19(3):429-35
pubmed: 15040831
Sleep. 2010 Jun;33(6):781-92
pubmed: 20550019